COMMUNIQUÉS West-GlobeNewswire

Novo Nordisk A/S - share repurchase programme
22/01/2024
Bagsværd, Denmark, 22 January 2024 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 [...]
Neumora Therapeutics Appoints Kaya Pai Panandiker as Chief Commercial Officer
22/01/2024
WATERTOWN, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced the appointment of Kaya [...]
Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea
22/01/2024
CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and [...]
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
22/01/2024
– Focus on Phase 2/3 program in notalgia paresthetica (NP), a neuropathic disorder with significant unmet need – – Phase 3 program in advanced chronic kidney disease (CKD) to be discontinued – – Planned workforce [...]
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine
22/01/2024
Lead vaccine candidate selected for advancement against synucleinopathies including Multiple System Atrophy, Parkinson’s disease and Dementia with Lewy bodies CAMBRIDGE, Massachusetts and TORONTO, Ontario, Jan. 22, 2024 [...]
Sagimet Biosciences Announces Positive Topline Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 NASH
22/01/2024
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial of 168 NASH patients with stage 2 or 3 fibrosis Primary efficacy endpoints: NASH resolution [...]
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy
22/01/2024
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy ProteinLogic, Cambridge, UK and Stellenbosch University, South Africa [...]
NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services
22/01/2024
NMD Pharma Appoints Morten Bull as SVP, General Counsel and Head of People & Business Services Aarhus, Denmark, 22 January 2024 – NMD Pharma A/S, a clinical-stage biotech dedicated to developing novel and improved [...]
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
22/01/2024
AC Immune to Regain Global Rights to Crenezumab and Semorinemab Company’s strategy is focused on advancing the Phase 2 development of its three active immunotherapies Active immunotherapy now considered to be the [...]
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
22/01/2024
ZUG, Switzerland, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, [...]
BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer
22/01/2024
The pivotal Phase 3 trial with BNT323/DB-1303 follows positive Phase 1/2 safety and efficacy data in patients with Human Epidermal Growth Factor Receptor 2 (“HER2”)-expressing advanced solid tumors with early signs of [...]
Oculis to Host In-Person & Virtual R&D Day in New York on February 28, 2024
22/01/2024
ZUG, Switzerland, and BOSTON, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or “the Company”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, [...]
Bionomics Provides a Review of 2023 and of 2024 Plans
22/01/2024
Positive Phase 2b data announced for BNC210 on reduction of total symptom severity and multiple symptom clusters in post-traumatic stress disorder (PTSD), with a discussion with the U.S. Food & Drug Administration ( [...]
Telix Highlights Presentations at Upcoming ASCO Genitourinary Cancers Symposium (ASCO GU 2024)
22/01/2024
MELBOURNE, Australia, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces presentations featuring the Company’s theranostic programs at the upcoming American [...]
Sosei Heptares Webinar Presentation for FY2023 Financial Results
22/01/2024
Tokyo, Japan and Cambridge, UK, 22 January 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 12 months ended 31 [...]
Calibre Scientific Acquires RUWAG, a Swiss Provider of Diagnostics and Life Sciences Products and Services
22/01/2024
LOS ANGELES, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Calibre Scientific is pleased to announce the acquisition of RUWAG Handels AG (“RUWAG” or the “Company”), a provider of diagnostics and life sciences products and services [...]
Calibre Scientific fait l’acquisition de RUWAG, un fournisseur suisse de produits et de services pour le diagnostic et les sciences de la vie
22/01/2024
LOS ANGELES, 22 janv. 2024 (GLOBE NEWSWIRE) -- Calibre Scientific a le plaisir d’annoncer l’acquisition de RUWAG Handels AG (« RUWAG » ou la « Société »), un fournisseur de produits et de services pour le diagnostic et [...]
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy
22/01/2024
ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy ProteinLogic, Cambridge, UK and Stellenbosch University, South Africa [...]
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
22/01/2024
– Transaction aligns to Coherus’ strategic focus on oncology – – Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“ [...]

Pages